Kyowa Hakko Kirin Starts Phase III Study For Coagulation Drug
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin has commenced a Phase III trial in Japan for KW-357 to treat patients with disseminated intravascular coagulation